Transplant Research Innovation — International Network — Data Initiative
Harmonizing clinical, histological, immunological, virological and molecular data from patient populations worldwide — to advance precision medicine in solid organ transplantation.
The TRINITY consortium gathers its principal investigators and partners for a private dinner hosted at the Residence of the Consul General of France, on the occasion of the American Transplant Congress. An evening of Franco-American science, collaboration and friendship — celebrating the people behind the data.
Built on the data-driven methodology of the iBox prognostic system — now an EMA-qualified surrogate endpoint for clinical trials.
Despite advances in immunosuppression, kidney transplant recipients still face significant risks from rejection, viral infection, disease recurrence and graft failure. Early detection and accurate risk stratification remain unmet needs.
Single-center studies, while foundational, cannot account for the heterogeneity in immunological risk, immunosuppressive strategies and clinical practice that exists across transplant populations worldwide. TRINITY was established to close this gap — building a shared, evolving research infrastructure that enables multicenter validation at scale.
Each project operates on the same harmonized datalake, with distinct scientific objectives and data requirements.
A prognostic system for kidney allograft failure, integrating eGFR, proteinuria, histology and immunology. Already validated across seven countries and randomized trials; TRINITY extends it to new centers and populations.
A non-invasive biomarker of graft injury. TRINITY validates the dd-cfDNA model across cohorts and evaluates its association with Banff 2022 microvascular inflammation phenotypes and early post-transplant settings.
One of the largest international BK cohorts in kidney transplantation — integrating viral loads with biopsy findings, dd-cfDNA and outcomes to identify risk factors and build progression-risk tools.
An undercharacterized contributor to graft loss. TRINITY defines the incidence and impact of recurrence across IgA nephropathy, FSGS, membranous and membranoproliferative disease — distinguishing recurrence from rejection.
Data are extracted locally after IRB approval and transferred through secure, end-to-end encrypted protocols.
Local extraction following IRB approval, then secure transfer into the consortium pipeline.
→Cleaning, harmonization and mapping to a common data model of 400+ variables.
→Integration into a centralized, cloud-based repository with end-to-end encryption.
→Real-time querying, visualization and machine-learning pipelines on harmonized data.
Pr. Loupy's research focuses on the development and validation of prognostic models and molecular biomarkers in kidney transplantation. He led the development of the iBox system and the large-scale evaluation of dd-cfDNA for rejection detection.
TRINITY's coordination — data harmonization, quality control and analytical planning — is centrally managed at the Paris Institute for Transplantation & Organ Regeneration. The initiative convenes biannually to review results and define research priorities.
A combined cohort exceeding 40,000 patients — with established data-use agreements and IRB approvals at every site.
Centers interested in joining, or contributing data to specific projects, are warmly invited to contact the coordinating team. Investigators may also propose new research projects aligned with the consortium's scientific priorities.